Siddoway L A, Roden D M, Woosley R L
Cardiovasc Clin. 1985;15(3):199-248.
The number of antiarrhythmic drugs available in the United States is increasing, with the discovery of antiarrhythmic properties of drugs previously marketed for other indications (phenytoin, imipramine) and the development of several new drugs, many of which are likely to become commercially available in the next 5 years. The currently available drugs and several promising investigational drugs are reviewed in this report. Their optimal use is dependent on an understanding of their electropharmacologic effects, pharmacokinetics, drug interactions, and clinical pharmacology. Such use may allow better attempts to reduce arrhythmia-related death and morbidity.
在美国，可用的抗心律失常药物数量不断增加，这得益于先前用于其他适应症的药物（苯妥英、丙咪嗪）被发现具有抗心律失常特性，以及几种新药的研发，其中许多药物可能会在未来5年内上市。本报告对目前可用的药物以及几种有前景的研究性药物进行了综述。它们的最佳使用取决于对其电药理学效应、药代动力学、药物相互作用和临床药理学的了解。这种使用方式可能会更有效地降低与心律失常相关的死亡率和发病率。
